A First-in-human Research Study on How NNC0662-0419 Works in People Living With Overweight or Obesity

PHASE1CompletedINTERVENTIONAL

Enrollment

100

Participants

Timeline

Start Date

December 18, 2024

Primary Completion Date

July 26, 2025

Study Completion Date

July 26, 2025

Conditions

OverweightObesity

Interventions

DRUG

NNC0662-0419

Participants will receive NNC0662-0419 subcutaneous (s.c.) once weekly.

OTHER

Placebo (NNC0662-0419)

Participants will receive placebo matched to NNC0662-0419 s.c. once weekly.

Trial Locations (1)

Celerion, Lincoln, Lincoln